Wound healing and local neuroendocrine regulation in the injured liver Mohammad R. Ebrahimkhani, Ahmed M. Elsharkawy and Derek A. Mann* The hepatic wound-healing response is a complex process involving many different cell types and factors. It leads to the formation of excessive matrix and a fibrotic scar, which ultimately disrupts proper functioning of the liver and establishes cirrhosis. Activated hepatic myofibroblasts, which are derived from cells such as hepatic stellate cells (HSCs), play a key role in this process. Upon chronic liver injury, there is an upregulation in the local neuroendocrine system and it has recently been demonstrated that activated HSCs express specific receptors and respond to different components of this system. Neuroendocrine factors and their receptors participate in a complex network that modulates liver inflammation and wound healing, and controls the development and progression of liver fibrosis. The first part of this review provides an overview of the molecular mechanisms governing hepatic wound healing. In the second section, we explore important components of the hepatic neuroendocrine system and their recently highlighted roles in HSC biology and hepatic fibrogenesis. We discuss the therapeutic interventions that are being developed for use in antifibrotic therapy. Hepatocytes are organised into epithelial plates and are primarily responsible for metabolic functions in the liver. Between the plates are the sinusoids, which are distensible vascular channels lined with sinusoidal endothelial cells (Fig. 1) . Small fenestrations in the sinusoidal linings allow direct cell-to-cell contact and free diffusion of many substances. Wound healing is the normal response of tissue to an injury, and liver fibrosis occurs as a result of repeated cycles of injury and repair. The cascade of events that establish hepatic fibrosis is complex, and is influenced by how different cell types in the liver interact in response to injury. Hepatic fibrosis and its end-stage -cirrhosis -are a major cause of mortality and morbidity worldwide. The most common causes of cirrhosis are alcohol abuse, hepatitis B, hepatitis C and, increasingly, obesity, which leads to the metabolic syndrome that can be complicated by non-alcoholic fatty liver disease (NAFLD). Other less-common causes include primary biliary cirrhosis, haemochromatosis, autoimmune hepatitis and primary sclerosing cholangitis.
Research over the past decade has greatly improved our knowledge of the cellular and molecular biology of fibrosis in the liver. Several high-profile papers have shed new light on the important roles that hepatic neuroendocrine pathways play in the processes of wound healing and regeneration in the liver. These functions are also being increasingly recognised in different organs (Refs 5, 6, 7) . The hepatic neuroendocrine system is upregulated in the liver following injury and can regulate the pattern of wound healing and hepatic regeneration in different ways. In this review, we will highlight some of the molecular mechanisms underlying hepatic wound healing and address recent advances in understanding the role of the neuroendocrine system in liver fibrosis. The fact that many modulators of neuroendocrine factors are already in widespread clinical use makes this field particularly exciting. There is now, more than ever, a need to generate effective antifibrotic therapies in a world where mortality from liver disease will see exponential growth as a result of the current obesity epidemic, as well as increasing burdens from alcohol abuse and viral hepatitis. 
Hepatic wound healing
The normal resolution of tissue injury involves a series of precise orchestrated phases: (1) inflammation; (2) production of cytokines and growth factors; (3) myofibroblast activation; (4) extracellular matrix (ECM) production; (5) angiogenesis; (6) maturation; and (7) remodelling, which eventually leads to scar elimination and a return of injured tissue to the normal state (Refs 8, 9) (Fig. 2) . Inappropriate tissue repair and pathological scarring occurs if any element of this intricate process becomes interrupted or overactivated. An imbalance between ECM formation and degradation can lead to the accumulation of ECM: an outcome known as fibrosis (Ref. 9) (Fig. 2) . Fibrosis is the final general consequence of uncontrolled repair processes in many organs in response to a wide variety of chronic insults and ultimately can disable proper functioning of the organ. It is known to occur in the liver, pancreas, lungs, heart, kidneys, eyes and skin. Over the past decade, there has been extensive investigation of the molecular events underlying tissue fibrogenesis. In the following sections, we explore the mechanism of hepatic wound healing and describe the cellular compartments in which it occurs.
The inflammation-fibrosis pathway
Chronic persistent inflammation typically precedes fibrosis ( Refs 10, 11, 12) . Following injury to the liver, hepatocytes release factors that start an inflammatory process by recruitment of leukocytes to the site of injury. Local production of matrix metalloproteinases (MMPs) at the site of injury results in the disruption of the basement membrane and favours inflammatory cell infiltration (Ref. 13) . Neutrophils are the most abundant inflammatory cell in the early stages of wound healing. Their granulation is followed by macrophage infiltration and subsequently by lymphocyte recruitment (Refs 8, 12) . The primary roles of leukocytes are to eliminate any invading organisms and to remove dead cells (Ref.
12). Inflammation also produces profibrogenic cytokines and chemokines, which activate myofibroblasts and induce woundhealing responses, which, if unchecked, drive fibrogenesis (Fig. 2) . However, it has also been proposed that fibrosis is not always driven by inflammation, suggesting that the mechanisms that regulate fibrogenesis partly differ from those regulating inflammation (Ref. 8) . This might explain the lack of efficacy of some antiinflammatory agents in the treatment of fibrotic disease and the need to identify targeted antifibrotic therapies.
Myofibroblasts: the key players in hepatic fibrosis
In many organs, including the liver, myofibroblasts are the key cellular effectors during wound contraction and repair, and inappropriate myofibroblast activation is the central pathogenic mechanism of fibrotic disorders (Ref. 14) . Upon tissue injury, myofibroblasts become activated and migrate toward the site of damage where they proliferate. Myofibroblasts produce ECM proteins, such as type I and type III collagen, and control ECM remodelling through the expression of several MMPs and tissue inhibitors of metalloproteinases (TIMPs). The balance between ECM degradation and production is a critical factor that determines the normal wound-healing response and returns the tissue to its preinjury state (Ref. 15 ). This process is influenced by the number of activated myofibroblasts at the site of injury, which is controlled by the rate of production and proliferation as well as apoptosis of these cells (Refs 9, 16). Chronic injury induces a marked alteration in the normal healing process and prevents return of tissue to the preinjury state. In fact, constant inflammation and/or infection leads to permanent myofibroblast activation, either directly, by acting on HSCs or indirectly, through paracarine-dependent factors (Fig 2) . This activated phenotype of myofibroblasts promotes the inappropriate regulation of tissue repair and leads to extensive scar formation, and finally results in fibrosis (Ref. 17) (Fig. 2) .
Developmentally, fibroblasts are mesenchymal in origin (Ref. 18) . However, it is now widely believed that myofibroblasts are derived from a number of different sources in injured adult tissues (Ref. 19 ). In the context of the liver, there are four different cellular sources (Fig. 3) Little is known of the functional role of neuroendocrine cells in many organs. It has been suggested that they probably serve a paracrine or local regulatory role. Neuroendocrine differentiation has been found in a subgroup of various carcinomas, including prostate, breast, stomach, colorectal and non-small-cell lung cancer (Refs 62, 63, 64, 65, 66, 67, 68) . In many of these tumours, neuroendocrine differentiation has adverse prognostic effects, suggesting an integral role for neuroendocrine factors in the regulation of the malignant phenotype (Refs 62, 63, 64). The detailed molecular mechanisms underlying the observed behaviour are mainly undefined but the neuroendocrine cells of the tumour probably play a significant role during tumour growth, angiogenesis and metastasis 
During chronic hepatic injury, different types of liver cells acquire a neuroendocrine phenotype. Given the putative role of the neuroendocrine system in the regulation of growth and survival in various conditions, and the shared similarities between tumours and wounds, the neuroendocrine compartment of the inflamed liver might be expected to regulate cell growth, migration and angiogenesis during wound healing. In fact, there is increasing evidence that local neuroendocrine factors do indeed influence wound healing and fibrogenesis in many organs (Refs 5, 6, 74, 75, 76, 77 However, there is clearly a need to study how much of this data can be extrapolated to liver inflammation and fibrosis.
In addition, signals derived from the ECM can also influence neuroendocrine functions in bile duct epithelial cells. It has been reported that interaction of these cells with the surrounding matrix -in particular collagen type IV and matrix heparan sulfate proteoglycan perlecaninduces neuroendocrine differentiation (Ref. 56) . This is consistent with the fact that reactive bile ductules are always surrounded by basement membrane containing these ECM components. Therefore, the neuroendocrine phenotype in cholangiocytes and other cellular populations in the liver can be regulated by signals from both the matrix and inflammatory factors. However, the specific cellular and molecular players that promote neuroendocrine differentiation in the liver remain to be identified.
Neuroendocrine regulation of myofibroblast differentiation and wound healing
As discussed earlier, transdifferentiation of HSCs into activated myofibroblasts is one of the pivotal events during wound healing and fibrogenesis in the injured liver, and can be subdivided into an initiation phase and a perpetuation phase. After liver injury, inflammatory cells may directly contribute to this transdifferentiation; but they are not likely to provide all the growth factors necessary for maintaining or accentuating the activated phenotype at later stages. However, induction of neuroendocrine differentiation in cholangiocytes and oval cells in response to inflammation and/or other mechanisms can contribute to maintenance of the activated state of HSCs. This may occur in parallel to the expression of various neuroendocrine receptors during HSC differentiation, which renders these cells responsive to regulation (Fig. 4) . Many of these factors can further affect hepatic wound healing by influencing neoangiogenesis, inflammation and hepatocyte regeneration. It should also be considered that HSCs have their own neuroendocrine features that may contribute to their fibrogenic activities via autocrine mechanisms. Here we discuss some of the recently identified neuroendocrine factors that regulate the production and function of HSC-derived myofibroblasts in the liver (Table 1) . It is interesting that many medications that could potentially modulate the effect of neuroendocrine factors and prevent fibrogenesis are already in routine clinical practice in other contexts and have established safety records, making them very attractive candidates for rapid translation into clinical trials. However, it is important to stress that the regulation of HSC biology by these factors has not yet been fully defined and may be more complex than initially anticipated. Furthermore, there is no evidence that neuroendocrine factors regulate the functions of HSC-derived myofibroblasts exclusively. In fact, the role of these factors in the differentiation of other cellular sources of liver myofibroblasts is possible and warrants further study.
Neutrophins and their receptors
Neutrophins were originally reported to regulate growth and development in the nervous system. A rapidly growing body of evidence now suggests that neutrophins also play profound . Local neuroendocrine regulation of stellate cell transdifferentiation. Normal hepatic structure is disrupted following injury to the liver, subsequently, quiescent stellate cells (q-HSCs) transdifferentiate into activated myofibroblasts (a-HSCs). At the same time, inflammation and altered matrix components induce neuroendocrine differentiation in proliferating bile ducts, oval cells and even HSCs. These cells produce various neuropeptides -endocannabinoids, serotonin, opioids, neutrophins -which contribute to maintenance and amplification of the differentiated phenotype in activated myofibroblasts. Neuroendocrine factors contribute to various aspects of profibrogenic activity in activated myofibroblasts, such as contraction, migration, proliferation and extracellular matrix production.
roles in various non-neuronal tissues. The neurotrophin family consists of nerve growth factor (NGF), brain-derived neurotrophin (BDNF), neurotrophin 3 and neurotrophin 4/5. The neutrophin receptors are high-affinity neurotrophin tyrosine kinase receptors TrkA, TrkB and TrkC, as well as the 'low'-affinity panneurotrophin receptor p75NTR, which belongs to the TNF-receptor superfamily (Table 1) Interestingly, an exon-3 knockout of p75, which retains an intact intracellular domain but lacks the structural requirements for interaction with its ligand, supports the activation of HSCs and the development of liver fibrosis in a predictable manner after carbon tetrachloride (CCl 4 ) intoxication (Iredale, J.P. and Kendall, T.J., University of Edinburgh, UK, pers. commun.). It has been suggested that p75 
The serotonin system
Serotonin or 5-hydroxytryptamine (5-HT) has been recognised for more than 50 years as an effector on various types of smooth muscle cell and subsequently as an agent that enhances platelet aggregation and as a neurotransmitter in the nervous system. Despite the critical role of serotonergic mechanisms in the central nervous system, the brain actually contains very little serotonin in relative terms. About 95% of serotonin is produced in enterochromaffin cells throughout the gut. Enterochromaffin cells produce far more serotonin than is required by the gut and it overflows into the blood, where it is then taken up and concentrated in platelets, the only source of blood serotonin. After its release by platelets, serotonin is absorbed rapidly by various cell types via the specific membrane-bound serotonin transporter (Ref. 94 ). Molecular cloning has revealed an unexpected diversity of receptor subtypes in serotonin signalling (5HT1 -5HT7), which are coupled to different, but overlapping, transmembranesignalling mechanisms ( 
Endogenous opioid peptides
Opiates have been known for decades for their role in pain management. They have been shown to be produced endogenously in the body and to regulate cell growth, differentiation and survival in neuronal and non-neuronal cells. Endogenous opioid peptides act by interacting with three classical opioid receptors: the m, d and k receptors ( 
Future perspectives and therapeutic potentials
The role of the neuroendocrine system in liver disease is an important emerging theme that has already shed new light on the molecular mechanisms that regulate hepatic wound healing and fibrogenesis. However, much remains to be learned before this new information can be exploited for therapies that promote liver regeneration and limit fibrosis. In particular, the presence of different receptors with counteracting signalling events means that fibrosis of the liver is a far from simple event. In future, we need to furtherdissect the expression and function of different neuroendocrine factors and the related receptors in each cell population of the liver with precise molecular biology approaches. For example, the increasing availability of cell-specific knockouts of different serotonin receptors will enable a careful dissection of the role of the various receptors in vivo. Furthermore, there is an urgent need to confirm the results in human cells and both normal and diseased human tissues.
Serotonin antagonists and reuptake inhibitors are used routinely for the management of psychiatric disorders such as depression. Naltrexone (a nonselective opioid-receptor blocker) is clinically administered for the treatment of cholestatic pruritis in primary biliary cirrhosis and also in the management of addiction and alcohol dependence (Refs 112, 113). CB1 antagonists are currently under trial for the treatment of obesity (Ref. 114 ). The antagonist used in a recent study on the role of CB1 in liver fibrosis in mice is SR141716A (rimonabant) (Ref. 108); this drug is currently an available therapeutic option. Although there have been no studies on the role of these drugs in the progression of human liver disease, their availability in clinical practice makes it likely that clinical trials of these agents in chronic fibrogenic hepatic disease will not be far off.
Portal hypertension, variceal bleeding and systemic arterial vasodilatation are among the main reasons for morbidity and mortality in cirrhotic patients. It has been demonstrated that some of the neuroendocrine factors, such as endogenous cannabinoids and opioids, contribute to the systemic vasodilatory state seen in cirrhosis (Ref. 115) . Therefore, modulation of these systems can potentially extend the life of cirrhotic individuals, not only by slowing or reversing fibrogenesis, but also by improving the associated hyperdynamic circulatory state. CB1 receptor activation has been linked to obesity and energy homeostasis, and its inhibition can exert enhanced antifibrotic effects by modulation of metabolic risk factors (Ref. 116 ). An important study has shown that serotonin plays a role in the pathogenesis of steatohepatitis, and therefore might represent a novel target for the prevention and treatment of nonalcoholic steatohepatitis (NASH) and its associated fibrosis (Ref. 117) . Opioid-receptor blockade by naltrexone is an approved strategy for treatment of alcohol dependence by reducing alcohol craving and relapse in heavy drinkers, and it may also prove to be a more effective antifibrotic candidate in alcoholic patients.
Conclusion
It is clear that local neuroendocrine systems play a critical role in the development of hepatic fibrosis. Various modulators of different components of this system are available clinically and can be potentially useful in patients with liver disease. However, to achieve further successful therapeutic goals through neuroendocrine targeting in hepatic fibrosis, we need to consider the timing of treatment in the course of disease and the duration of the therapy, as well as celland receptor-specific targeting. In addition, appropriate pharmacokinetics and safety margins of the drugs should be considered when treating patients with liver disease. 
